T:E2 Ratio Guide: Decision Tree, Dose Scenarios & AI Thresholds

You drew bloods, punched the numbers into a calculator, and got back a single figure. Maybe it was 14. Maybe 28. Maybe 60. Now what? The internet will happily tell you that anything below 10 is "estrogen dominance," anything above 30 means you need to back off the AI, and that the magic number is 20. That advice is half right and half dangerous, depending on the dose you are running and how your lab measured your estradiol.

This article is the interpretation layer for the T:E2 ratio calculator. The calculator does the math. This piece tells you what the number actually means in your context: TRT versus blast, with or without an AI, on test only versus stacked with EQ, Tren, or Deca, and what to do if your estradiol looks too low or too high relative to your testosterone.

What the T:E2 ratio actually tells you

Estradiol is not a waste product. The aromatase enzyme converts roughly 0.3 percent of circulating testosterone into estradiol in men, and that small fraction does heavy lifting: bone preservation, cardiovascular protection, libido, mood regulation, erectile function, body composition. The ratio of total testosterone to estradiol gives you a single number that captures the balance between androgenic and oestrogenic signalling. When one drifts too far from the other, problems start appearing even if both individual values look "in range."

The standard calculation is testosterone in ng/dL divided by estradiol in pg/mL. So a man at 800 ng/dL total T (about 28 nmol/L for AU/UK readers) and 40 pg/mL E2 (about 147 pmol/L) has a ratio of 20. The calculator handles the unit conversions automatically if your lab reports in nmol/L or pmol/L. Every example below shows both units so you can read your bloodwork without doing the math in your head.

The ratio matters because absolute estradiol levels in men have a U-shaped relationship with health outcomes. Too low and you lose bone density, sexual function, and cardiovascular protection. Too high and you get gynecomastia risk, water retention, and emotional volatility. The ratio captures the "too low for your androgen state" versus "too high for your androgen state" in one figure, which is more useful for decision-making than either number alone in most TRT-range contexts.

Why the ratio matters more than absolute E2 alone

Two men can both have estradiol of 45 pg/mL (about 165 pmol/L). If the first is a natural male with total testosterone at 550 ng/dL (about 19 nmol/L), his ratio is 12. He might be running mild estrogen dominance, with water retention or mood symptoms. If the second is on 200 mg testosterone per week and tests at 1100 ng/dL (about 38 nmol/L) with the same E2 of 45, his ratio is 24. That is squarely in the typical TRT band. Same absolute E2, different physiology, different action.

The ratio normalises estradiol against the androgen substrate driving it. On TRT, where testosterone is the dial you can turn, that context matters. The Swislocki and Eisenberg 2024 review in World Journal of Men's Health is the most recent peer-reviewed treatment of the ratio concept and lands on 10 to 30 as the range "apparently associated with beneficial outcomes" in cross-sectional data. They are careful to note this is a descriptive range, not a treatment target.

What's a healthy testosterone to estradiol ratio?

The 10 to 30 band shows up across the observational literature, but it is worth knowing where the boundaries come from before you tattoo them on your forearm.

At the low end, ratios under 10 correlate with metabolic syndrome and cardiovascular markers. Ali Hamza et al. 2022 found a ratio cutoff of 8.4 predicted metabolic syndrome with 80.9 percent sensitivity and an odds ratio of 9.6. Pan et al. 2020 found inverse correlation between an elevated E2:T ratio and nocturnal penile tumescence in 235 men. Below 10 is consistently the zone where bad things start showing up in observational data.

At the high end, ratios above 30 to 40 raise concern for over-suppressed estradiol, particularly when an AI is in play. The U-shaped mortality relationship documented by Jankowska et al. 2009 in 501 men with systolic heart failure showed both the lowest and the highest quintiles of estradiol carried elevated all-cause mortality compared to the middle quintile. The population was sick at baseline, so the absolute numbers do not translate to healthy lifters, but the directional U-shape is consistent with mechanistic data: estradiol has its own job, and zeroing it out causes harm independent of testosterone.

The middle band, 10 to 30, is where most eugonadal men cluster and where outcomes are best in cross-sectional studies. That is the origin of the "sweet spot" framing.

Why "optimal" varies by protocol

The 10 to 30 range was derived from men with physiological testosterone levels. On TRT, where you are running at the high end of normal or slightly above, the same range largely holds. On supraphysiological blasts, the math breaks down for a reason most people get backwards: aromatase saturates.

Lakshman et al. 2010 is the cleanest study on this. They dosed 51 young and 52 older men with testosterone enanthate at 25, 50, 125, 300, and 600 mg per week after suppressing endogenous production. Estradiol rose dose-dependently, but the conversion followed Michaelis-Menten saturable enzyme kinetics with an aromatase Km of 1.83 nM. In plain English: as testosterone climbs, aromatase produces proportionally less estradiol per unit of testosterone. The ratio numerically inflates at higher doses, even though absolute estradiol still rises substantially.

Finkelstein et al. 2013 in the New England Journal of Medicine reported clean dose-paired data using testosterone gel. At 1.25 g/day gel, men averaged 191 ng/dL T and 7.9 pg/mL E2, a ratio of 24. At 10 g/day gel they averaged 805 ng/dL T and 33.3 pg/mL E2, ratio 24. Steady-state ratios stayed in the 24 to 28 band across the entire dose range. This is reassuring evidence that, in steady state without injection peaks, the ratio is roughly stable across TRT and low-blast doses.

This has practical consequences. A ratio of 40 on a blast does not necessarily mean your E2 is low. It might mean aromatase is approaching saturation and the absolute E2 is appropriate for the testosterone you are running. Reaching for anastrozole to "fix" a high ratio at blast doses is one of the most common ways men accidentally crash their estradiol.

Running 200 mg test C: what should your T:E2 look like?

This is the section that nobody writes properly. People want dose-specific numbers, not generalities. Here are the practical bands synthesised from Finkelstein 2013, Lakshman 2010, the Pastuszak 2022 pharmacokinetics review, and what real bloodwork tends to show in TRT communities. Treat these as starting expectations, not narrow targets.

Typical TRT-dose ratio bands

On weekly injections, drawn mid-cycle (3 to 4 days post-injection on weekly dosing):

• 100 mg test C/E per week: trough total T roughly 400 to 600 ng/dL (14 to 21 nmol/L), E2 roughly 25 to 40 pg/mL (92 to 147 pmol/L), ratio roughly 15 to 20
• 150 mg per week: trough T roughly 600 to 800 ng/dL (21 to 28 nmol/L), E2 roughly 35 to 55 pg/mL (128 to 202 pmol/L), ratio roughly 15 to 20
• 175 to 200 mg per week: trough T roughly 700 to 1000 ng/dL (24 to 35 nmol/L), E2 roughly 40 to 70 pg/mL (147 to 257 pmol/L), ratio roughly 14 to 20
• Twice-weekly or EOD splits: ratios cluster tighter, less peak-trough variance

If you are at 200 mg per week and your bloods show 950 ng/dL T (33 nmol/L) with 45 pg/mL E2 (165 pmol/L), your ratio is 21. That is dead centre of the typical TRT band. No intervention needed. If you feel good, log it and keep going.

If the same person tests at 950 ng/dL T with 90 pg/mL E2 (330 pmol/L), ratio 10.5, with no symptoms, the right answer is probably not anastrozole. Check your assay (more on this below), draw again in 6 weeks, and only intervene if symptoms emerge.

Typical blast-dose ratio bands

The variance widens dramatically. Body fat percentage is the dominant modifier of aromatase capacity. Lakshman 2010 showed older men had 40 percent higher Vmax for aromatisation, driven by greater fat mass.

• 300 mg per week: peak T 1200 to 1600+ ng/dL (42 to 55+ nmol/L), E2 roughly 70 to 120 pg/mL (257 to 441 pmol/L), ratio roughly 12 to 18
• 500 mg per week: peak T 1500 to 2500+ ng/dL (52 to 87+ nmol/L), E2 roughly 100 to 180 pg/mL (367 to 661 pmol/L), ratio roughly 12 to 16
• 750 mg per week and up: highly variable, aromatase substantially saturated, individual response dominates

The pattern here is the opposite of what many people expect. At blast doses, the ratio compresses toward the lower end of the typical range because absolute E2 is high. If your 500 mg/week bloodwork shows a ratio of 14, that is normal. Reaching for an AI to push it into the 20s is how people develop joint pain, lipid crashes, and zero libido on 1000 ng/dL (35 nmol/L) of testosterone.

When the ratio "should" be lower than the sweet spot

The single most common mistake at blast doses is misreading a low ratio as a problem. If you are running 500 mg test per week and your ratio is 14, you do not have estrogen dominance. You have higher aromatase substrate. As long as you do not have symptoms (sensitive nipples, water retention to the point of obvious bloating, emotional volatility, mood swings, soft erections despite high libido), the ratio is doing exactly what physiology predicts.

The threshold for intervention at blast doses should be both a low ratio (under 10 to 12) AND clear estrogen-excess symptoms. One without the other is not enough.

Should you add an AI based on your T:E2? A decision tree

This is where most articles either dodge the question or hand you a formula that ignores your actual bloodwork. Here is a four-question decision tree drawn from the evidence.

Question 1: What assay did your lab use?

If you got a "standard" or "direct" estradiol assay (the default at most clinics), your number is probably inflated. Handelsman et al. 2014 tested 5 commercial direct immunoassays against gold-standard LC-MS/MS in 101 healthy men. All 5 immunoassays showed positive bias ranging from 6 to 74 percent. The reason: estradiol has more than 100 metabolites in serum, some of which cross-react with the immunoassay antibodies, inflating the reading.

Rosner et al. 2013 is the Endocrine Society's formal position statement: very low estradiol concentrations, which is the normal range for men (10 to 40 pg/mL), cannot be accurately measured by routine immunoassay. They recommend LC-MS/MS (often labelled "sensitive estradiol") for all male E2 measurements.

Practical rule of thumb: if your lab used a standard immunoassay, your true E2 is probably 20 to 40 percent lower than the printed value. A "concerning" 60 pg/mL (220 pmol/L) on immunoassay might be 40 to 48 pg/mL (147 to 176 pmol/L) on a sensitive assay. Before reaching for an AI, get a sensitive assay reading.

If the assay was already LC-MS/MS or sensitive, proceed to Question 2 with the number as printed.

Question 2: What direction are your symptoms pointing?

The ratio itself does not tell you which direction is the problem. Symptoms do.

Estrogen excess looks like: sensitive or puffy nipples, water retention with visible facial puffiness or rapid bodyweight gain, emotional blunting or mood swings, soft erections despite high libido, gynecomastia tissue formation (palpable lump behind the nipple).

Estrogen deficiency looks like: joint dryness or aching (especially knees and elbows), dry skin, brittle hair, low or absent libido, anhedonia or flat mood, difficulty getting erections despite normal testosterone, a worsening lipid panel (HDL crash), insomnia.

If you have no symptoms in either direction and your ratio is in the 10 to 30 range, do nothing. The number alone is not an emergency.

Question 3: What is your ratio plus absolute E2?

Combine ratio with the actual estradiol number:

• Ratio under 10 AND symptoms of E2 excess AND E2 over 50 pg/mL (about 184 pmol/L) on sensitive assay: AI consideration is reasonable
• Ratio under 10 AND no symptoms: more bloodwork in 6 weeks, no intervention
• Ratio 10 to 30 AND no symptoms: no action
• Ratio 30 to 50 AND no symptoms: no action (likely normal for the dose or assay artifact)
• Ratio over 40 AND symptoms of E2 deficiency: AI is overdosed or unnecessary, reduce or stop

The "ratio under 10 plus symptoms plus elevated absolute E2" combination is the only configuration that strongly supports starting an AI. Anything weaker than that warrants more data first.

Question 4: What is your dose context?

A ratio of 14 on 200 mg test/week is different to a ratio of 14 on 500 mg test/week. At TRT doses, that ratio is on the low side of normal and worth watching. At blast doses, it is exactly what aromatase saturation predicts. The dose context determines how much weight to put on the ratio number alone.

Anastrozole versus exemestane versus nothing

If you decide an AI is warranted, the literature on which AI to use in men is thin. There are no head-to-head randomised trials of anastrozole versus exemestane in TRT or AAS-using men. All comparison data come from oncology trials in women.

The mechanistic difference is real. Anastrozole is a non-steroidal reversible competitive inhibitor. Exemestane is a steroidal irreversible (suicide) inhibitor that permanently inactivates each aromatase molecule it binds. When you stop anastrozole, aromatase recovers within hours. When you stop exemestane, the effect persists until new enzyme is synthesised, roughly 2 to 3 days.

Leder et al. 2004 is the closest thing to a male anastrozole dosing trial. They gave 37 elderly hypogonadal men anastrozole 1 mg/day or 1 mg twice weekly for 12 weeks. Daily dosing raised total T from 343 to 572 ng/dL and dropped E2 from 26 to 17 pg/mL. The point: 1 mg daily reduced E2 by only 35 percent in physiological-T men. At blast doses with massive aromatase substrate, the same dose has different proportional effect, which is why bodybuilding protocols sit at 0.25 to 0.5 mg every other day or three times weekly.

Burnett-Bowie et al. 2009 followed older hypogonadal men on anastrozole 1 mg/day for a year. Testosterone normalised but body composition and strength did not improve, despite the higher T levels. That finding alone matters: an AI in men is not "free" upside, and the broader literature on E2 suppression (Finkelstein above, plus the bone resorption signal in that study) points to real long-term costs.

The "exemestane is gentler on lipids" claim is widely repeated in bodybuilding spaces but the evidence base for that comparison in men is essentially absent. Mechanistically, exemestane is structurally a steroid (a derivative of androstenedione) and has weak androgenic activity of its own, which is the basis for the "less suppressive" claim. No male RCT proves it.

For gynecomastia specifically, SERMs are the better tool. Lawrence et al. 2004 showed raloxifene and tamoxifen both reduced breast nodule diameter in pubertal gynecomastia, with raloxifene producing more than 50 percent reduction in 86 percent of subjects. SERMs block estrogen at the breast receptor without suppressing systemic E2, so they avoid the bone density and lipid costs of an AI. If your problem is gyno tissue and not systemic high-E2 symptoms, a SERM is the targeted intervention.

Why crashing E2 is worse than running it slightly high

Finkelstein 2013 is the mechanistic study every TRT user should know. They used goserelin to suppress endogenous hormones in 400 men, then randomised them to varying testosterone doses with or without anastrozole. When estradiol was suppressed but testosterone maintained: fat mass increased significantly (p=0.001), sexual desire fell, and erectile function worsened (p=0.032) even with adequate testosterone. The conclusion: estradiol independently regulates body composition, sexual function, and bone homeostasis in men.

This is why the harm-reduction default is to leave E2 alone when in doubt. A high ratio with no symptoms beats a "perfect" ratio with crashed estradiol every time.

Anastrozole versus exemestane mechanistic differences and a full comparison live at /compare/anastrozole-vs-exemestane.

Compound stack context: how EQ, Tren, Mast, and Deca shift your ratio

The T:E2 ratio was developed for testosterone-only contexts. Once you add non-aromatising or progestogenic compounds, the ratio starts measuring something different to what you think it is measuring.

Test + EQ

Equipoise (boldenone undecylenate) has a reputation as a "natural AI" via its supposed ATD (androsta-1,4,6-triene-3,17-dione) metabolite. The peer-reviewed evidence for this claim is weak to nonexistent in humans. Parr et al. 2009 showed ATD is a parent compound that metabolises to boldenone, not the other way around. The mainstream bodybuilding claim has the metabolic direction backwards.

What likely happens in practice: boldenone competes with testosterone at the aromatase enzyme, producing its own oestrogenic metabolite called boldenone-estrogen, which is structurally distinct from estradiol-17β. Sensitive LC-MS/MS would measure this as somewhat lower-than-expected estradiol; immunoassay platforms may cross-react inconsistently. The practical result: on test plus EQ, your E2 reading is often lower than the testosterone dose alone would predict, but the effect is unreliable and not a substitute for an AI when one is actually needed.

The article EQ and estrogen ratio: how boldenone shifts your E2 covers this in more depth.

Test + Tren

Trenbolone cannot aromatise. Yarrow et al. 2010 reviewed trenbolone's tissue selectivity and reduced estrogenic activity relative to testosterone: the structural features that make it a potent androgen also make it a poor aromatase substrate. So on test plus tren, your serum E2 will be whatever the test alone produces, unchanged by the tren.

That is the trap. Tren is strongly progestogenic. Bauer et al. 2000 showed 17β-trenbolone has slightly higher affinity to the progesterone receptor than progesterone itself. This drives gynecomastia, water retention, libido swings, and emotional volatility through a pathway that does not show up on any standard bloodwork. Your estradiol can look fine while your symptoms suggest estrogen excess, because the actual driver is progestin activity at progesterone receptors.

The practical implication: on a tren cycle, the T:E2 ratio loses most of its predictive value for symptom management. Treat symptoms, not the ratio.

Test + Mast

Masteron (drostanolone) is a 2α-methylated DHT derivative. It is not a substrate for aromatase and cannot aromatise. Its mild anti-estrogenic effect operates via two probable mechanisms: competitive binding at aromatase as a non-productive substrate (reducing E2 output from testosterone), and possibly direct estrogen receptor interactions documented in the breast cancer treatment literature where drostanolone was clinically used in the 1960s to 1980s.

On test plus mast, E2 tends to run 10 to 30 percent lower than test-alone at the same testosterone dose, depending on the masteron dose. T:E2 ratio rises modestly. The effect is real but mild, not equivalent to an AI. Do not stack mast and anastrozole expecting "doubled" E2 suppression; you are likely to crash your estradiol.

Test + Deca

This is the most counterintuitive stack. Nandrolone aromatises at roughly 20 percent of testosterone's rate, and some studies find essentially no conversion at all. The bigger issue is that nandrolone suppresses your endogenous testosterone production (and thus your baseline aromatase substrate) while contributing almost nothing to estradiol itself.

Friedl et al. 1991 is the canonical study. Men given 300 mg per week nandrolone decanoate alone showed serum estradiol drop from 40 to 14 pg/mL (a 65 percent decline). Men given 300 mg testosterone enanthate alone saw estradiol rise from 32 to 79 pg/mL.

On test plus Deca, the test component maintains E2 from its own aromatisation; the Deca component does almost nothing to E2 but adds significant progestogenic activity. Nandrolone has approximately 5 to 20 times the progesterone receptor affinity of testosterone. The famous "Deca dick" phenomenon is likely driven by some combination of progesterone-mediated effects on libido via hypothalamic progesterone receptors, prolactin elevation, dopaminergic effects, and in some cases low-E2 symptoms when the test dose is too low to keep estradiol in range. The full picture is in Nandrolone bloodwork: understanding Deca dick.

The T:E2 ratio on Deca can look completely normal while you have classic estrogen-deficiency symptoms (because absolute E2 is low) or classic progestin-excess symptoms (which the ratio cannot capture).

The "ratio trap": same number, different physiology

A T:E2 ratio of 20 sounds like a single state. It is not. Consider these two scenarios:

Both ratios are exactly 20. The first man is functioning well. The second is symptomatic across the board: low libido, fatigue, joint aches, poor recovery, and bone resorption markers heading the wrong way.

Panken et al. 2025 demonstrated this empirically. In a large fertility cohort, the median T:E2 ratio in fertile men was 14.5 and in subfertile men was 15.0, essentially identical. The ratio alone could not distinguish between the two states. Absolute concentrations did.

Symptoms that distinguish the two states

If your ratio is in the "normal" range but you feel awful, look at the absolutes:

Both numbers low (T under 500 ng/dL or 17 nmol/L AND E2 under 25 pg/mL or 92 pmol/L): you are deficient across the board. The fix is not to chase the ratio. Raise the testosterone with proper TRT dosing and let estradiol follow naturally.

Both numbers in range but symptoms of estrogen excess despite "normal" ratio: check progesterone-receptor activity if on tren or Deca. The ratio is missing the actual problem.

Both numbers high (T over 1500 ng/dL or 52 nmol/L AND E2 over 80 pg/mL or 294 pmol/L) on a blast: ratio looks reasonable, but absolute E2 is elevated enough to cause symptoms in sensitive individuals. The "normal" ratio is not protective at extreme absolutes.

The ratio is one data point. Always read the absolutes alongside it.

Unit conversion: nmol/L and pmol/L users

If your lab reports in SI units (Australian, UK, New Zealand, and most of the EU), you cannot just divide nmol/L by pmol/L and get a usable ratio. The published reference ranges all use ng/dL divided by pg/mL.

The conversion factors:

• Testosterone: nmol/L multiplied by 28.84 equals ng/dL (molecular weight 288.42 g/mol)
• Estradiol: pmol/L multiplied by 0.2724 equals pg/mL (molecular weight 272.38 g/mol)

The "meaningless division" error

If an Australian lab reports T = 25 nmol/L and E2 = 180 pmol/L, the wrong move is to divide 25/180 = 0.139. That number cannot be compared to any reference range. The correct sequence:

1. Convert T to ng/dL: 25 × 28.84 = 721 ng/dL
2. Convert E2 to pg/mL: 180 × 0.2724 = 49 pg/mL
3. Calculate ratio: 721 ÷ 49 = 14.7

The ratio is 14.7, which is in the typical TRT band. The raw SI division (0.139) is not a ratio in any clinically useful sense.

Worked examples for AU/UK lab formats

The blast row and the well-managed TRT row both show ratios near 14 to 15. Same ratio, very different physiology, which loops back to the ratio trap.

The T:E2 calculator handles this conversion automatically. Enter your numbers in whichever units your lab gave you, pick the unit dropdown, and it does the math. For TRT context in Australia specifically, see Starting TRT in Australia: lab units and clinical defaults.

Sensitive vs standard E2 assay: how it changes your ratio

This is the most important section for anyone who has ever been told their E2 is "too high" and offered an AI on the strength of a number alone.

Standard immunoassay estradiol (the default at most clinics) systematically over-reads in males. Handelsman et al. 2014 tested 5 commercial direct immunoassays against gold-standard LC-MS/MS in 101 healthy men. All 5 immunoassays showed positive bias of 6 to 74 percent. The mechanism is cross-reactivity with the dozens of estradiol metabolites circulating in male serum, which gold-standard mass spectrometry separates and immunoassay does not.

Practical implication: an immunoassay reading of 50 pg/mL (184 pmol/L) might be a true LC-MS/MS value of 30 to 42 pg/mL (110 to 154 pmol/L). A "borderline high" 60 pg/mL (220 pmol/L) might be 40 to 50 pg/mL (147 to 184 pmol/L) on the sensitive assay. Your T:E2 ratio looks worse on immunoassay than it actually is.

The Endocrine Society's 2013 position statement explicitly recommends LC-MS/MS for all male estradiol measurements (Rosner et al. 2013). Five years on, most clinics still default to immunoassay because it is cheaper and the lab has fewer SKUs to manage. Ask for the sensitive version when it matters.

How to test, time, and re-interpret over a cycle

The T:E2 ratio is a snapshot. If you take that snapshot at different points in your injection cycle, you will get wildly different ratios with no actual change in physiology. The Pastuszak 2022 pharmacokinetics review found peak-to-trough ratios for IM testosterone cypionate at 200 mg every 2 weeks of 2:1 to 5.3:1 depending on dose interval (Pastuszak et al. 2022). On weekly injections the swing is much smaller.

Best time to draw on TRT

For weekly injections, draw mid-cycle: 3 to 4 days after your most recent injection, in the morning. This gives a representative reading that approximates your average testosterone exposure.

For biweekly (every 2 weeks) injections, draw at day 7 (mid-cycle). Avoid day 1 (peak) or day 14 (trough) unless you specifically want to characterise those extremes.

Estradiol shows much less diurnal variation than testosterone in men, so timing is less critical for the E2 component, but Brambilla et al. 2007 found that two measurements in the same individual on different days differ by 18 to 28 percent on average and exceed 27 to 54 percent in a quarter of cases. A single reading is a snapshot, not a baseline. For meaningful interpretation, you want at least two consistent draws weeks apart before drawing conclusions. Blood test timing on TRT covers the full protocol in depth.

How the ratio shifts across a blast cycle

For someone running a 12-week test enanthate blast at 500 mg per week:

• Pre-cycle baseline: natural T (say 600 ng/dL or 21 nmol/L), low E2 (25 pg/mL or 92 pmol/L). Ratio approximately 24. No aromatase saturation.
• Week 1 to 2: T rises rapidly to supraphysiological levels. Aromatase substrate has surged, but enzyme capacity has a ceiling. E2 climbs but lags. The ratio temporarily rises before equilibrating.
• Week 4 to 6: Steady state approaches (5 to 6 half-lives, so 5 to 6 weeks for enanthate). Both T and E2 plateau. Aromatase is more fully saturated. E2 may be 80 to 120 pg/mL (294 to 441 pmol/L) without an AI. Ratio drops to 12 to 18 depending on body fat and SHBG.
• Week 8 to 12: If no AI, ratio stays stable at steady state. If an AI was introduced, E2 suppresses disproportionately, ratio rises sharply, and over-suppression is common.
• Post-cycle / PCT: Exogenous T clears over 4 to 6 weeks (test enanthate half-life is 7 to 8 days). Endogenous T remains suppressed. During washout, T falls faster than aromatase capacity normalises. E2 may stay transiently elevated relative to the recovering T, producing classic PCT symptoms: libido crash, mood instability, water retention without muscle. PCT bloodwork: what to expect covers this stage in detail.

The takeaway: a single ratio number means very little without knowing where you are in the cycle. Three to four ratios spaced across a cycle tell a coherent story; one snapshot does not.

Practical recommendations

• Use the T:E2 calculator for the math. It handles unit conversion and gives you cycle-profile context for the number it returns.
• Always read the ratio alongside both absolute values. A ratio of 20 with T = 800 ng/dL (28 nmol/L) and E2 = 40 pg/mL (147 pmol/L) is not the same physiology as a ratio of 20 with T = 400 ng/dL (14 nmol/L) and E2 = 20 pg/mL (73 pmol/L).
• Get LC-MS/MS (sensitive estradiol) before making AI decisions. Standard immunoassay over-reads in males by 6 to 74 percent depending on platform.
• Treat symptoms, not numbers. A ratio outside the 10 to 30 band without symptoms is not an emergency. A ratio inside the band with clear symptoms still warrants action.
• On blast doses, expect ratios to compress toward the lower end of the typical band. This is aromatase saturation, not estrogen dominance.
• On compound stacks (EQ, Tren, Mast, Deca), the ratio loses some predictive power for symptom management because the compounds shift E2 measurement, progesterone receptor activity, or both.
• If you do start an AI, start low (0.25 mg anastrozole twice weekly is a common starting point on TRT-range testosterone). Retest in 4 to 6 weeks. Adjust slowly.
• For gynecomastia tissue specifically, consider a SERM (tamoxifen or raloxifene) instead of a systemic AI. SERMs block estrogen at the breast receptor without crashing systemic E2.

Key takeaways

• The T:E2 ratio (testosterone in ng/dL divided by estradiol in pg/mL) typically lands between 10 and 30 in healthy eugonadal men. This is a descriptive band from observational data, not a controlled treatment target.
• On TRT, most people sit in the 15 to 25 zone. On blast doses, ratios compress toward 12 to 18 because aromatase saturates as testosterone rises, not because E2 is suppressed.
• The "ratio trap" is real: a ratio of 20 can describe a healthy TRT-dosed male or a deficient hypogonadal one. Always read both absolute values, not just the ratio.
• Standard immunoassay estradiol over-reads in males by 6 to 74 percent. Always confirm with LC-MS/MS (sensitive estradiol) before making AI decisions.
• The AI decision tree covers four questions: assay type, symptom direction, ratio plus absolute E2, dose context. Symptoms outweigh the number every time.
• Crashing E2 with an AI is worse than running it slightly high. Finkelstein 2013 demonstrated independent harms to body composition, sexual function, and bone density from suppressed estradiol even with adequate testosterone.
• On compound stacks (EQ, Tren, Mast, Deca), the ratio loses predictive value because each compound shifts either E2 measurement or symptom drivers (progesterone receptor activity) in ways the ratio cannot capture.
• For Australian and UK users: convert nmol/L and pmol/L to ng/dL and pg/mL before dividing. The raw SI division is not a clinically meaningful ratio.

---

References

1. Swislocki, A. L. M., & Eisenberg, M. L. (2024). A review on testosterone: Estradiol ratio - does it matter, how do you measure it, and can you optimize it? World Journal of Men's Health, 43(3), 453-464. PubMed
2. Finkelstein, J. S., Lee, H., Burnett-Bowie, S. A., Pallais, J. C., Yu, E. W., Borges, L. F., et al. (2013). Gonadal steroids and body composition, strength, and sexual function in men. New England Journal of Medicine, 369(11), 1011-1022. PubMed
3. Lakshman, K. M., Kaplan, B., Travison, T. G., Basaria, S., Knapp, P. E., Singh, A. B., et al. (2010). The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. Journal of Clinical Endocrinology & Metabolism, 95(8), 3955-3964. PubMed
4. Handelsman, D. J., Newman, J. D., Jimenez, M., McLachlan, R., Sartorius, G., & Jones, G. R. D. (2014). Performance of direct estradiol immunoassays with human male serum samples. Clinical Chemistry, 60(3), 510-517. PubMed
5. Rosner, W., Hankinson, S. E., Sluss, P. M., Vesper, H. W., & Wierman, M. E. (2013). Challenges to the measurement of estradiol: An Endocrine Society position statement. Journal of Clinical Endocrinology & Metabolism, 98(4), 1376-1387. PubMed
6. Leder, B. Z., Rohrer, J. L., Rubin, S. D., Gallo, J., & Longcope, C. (2004). Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. Journal of Clinical Endocrinology & Metabolism, 89(3), 1174-1180. PubMed
7. Burnett-Bowie, S. A., Roupenian, K. C., Dere, M. E., Lee, H., & Leder, B. Z. (2009). Effects of aromatase inhibition in hypogonadal older men: A randomized, double-blind, placebo-controlled trial. Clinical Endocrinology, 70(1), 116-123. PubMed
8. Jankowska, E. A., Rozentryt, P., Ponikowska, B., Hartmann, O., Kustrzycka-Kratochwil, D., Reczuch, K., et al. (2009). Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA, 301(18), 1892-1901. PubMed
9. Lawrence, S. E., Faught, K. A., Vethamuthu, J., & Lawson, M. L. (2004). Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. Journal of Pediatrics, 145(1), 71-76. PubMed
10. Yarrow, J. F., McCoy, S. C., & Borst, S. E. (2010). Tissue selectivity and potential clinical applications of trenbolone: A potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids, 75(6), 377-389. PubMed
11. Bauer, E. R., Daxenberger, A., Petri, T., Sauerwein, H., & Meyer, H. H. (2000). Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor. APMIS, 108(12), 838-846. PubMed
12. Friedl, K. E., Dettori, J. R., Hannan, C. J. Jr., Patience, T. H., & Plymate, S. R. (1991). Comparison of the effects of high dose testosterone and 19-nortestosterone to a replacement dose of testosterone on strength and body composition in normal men. Journal of Steroid Biochemistry and Molecular Biology, 40(4-6), 607-612. PubMed
13. Parr, M. K., Fusshöller, G., Schlörer, N., Opfermann, G., Piper, T., Rodchenkov, G., & Schänzer, W. (2009). Metabolism of androsta-1,4,6-triene-3,17-dione and detection by gas chromatography/mass spectrometry in doping control. Rapid Communications in Mass Spectrometry, 23(2), 207-218. PubMed
14. Pastuszak, A. W., Gittelman, M., Tursi, J. P., Jaffe, J. S., Schofield, D., & Miner, M. M. (2022). Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age. Andrology, 10(2), 209-222. PubMed
15. Brambilla, D. J., O'Donnell, A. B., Matsumoto, A. M., & McKinlay, J. B. (2007). Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clinical Endocrinology (Oxford), 67(6), 853-862. PubMed
16. Panken, E. J., Hayon, S., Greenberg, D. R., Kumar, S. K. S., Brannigan, R. E., & Halpern, J. A. (2025). Testosterone to estradiol ratios in fertile and subfertile men: A large cohort analysis. Urology, 195, 75-79. PubMed
17. Ali Hamza, M., Abdulhameed, A., & Ali Mansour, A. (2022). Total testosterone to estradiol ratio as a predictor marker of metabolic syndrome in males. Archives of Razi Institute, 77(1), 359-365. PubMed
18. Pan, D., Xu, Z. H., Gao, Q., Li, M., Guan, Y., & Zhao, S. T. (2020). Relationship between penile erection and the ratio of estradiol to testosterone: A retrospective study. Andrologia, 52(9), e13759. PubMed